Thrombocytosis portends adverse prognostic significance in patients with stage II colorectal carcinoma

DSpace/Manakin Repository

Thrombocytosis portends adverse prognostic significance in patients with stage II colorectal carcinoma

Citable link to this page

 

 
Title: Thrombocytosis portends adverse prognostic significance in patients with stage II colorectal carcinoma
Author: Guo, Tianhua; Krzystanek, Marcin; Szallasi, Zoltan; Szallasi, Arpad

Note: Order does not necessarily reflect citation order of authors.

Citation: Guo, Tianhua, Marcin Krzystanek, Zoltan Szallasi, and Arpad Szallasi. 2014. “Thrombocytosis portends adverse prognostic significance in patients with stage II colorectal carcinoma.” F1000Research 3 (1): 180. doi:10.12688/f1000research.4856.2. http://dx.doi.org/10.12688/f1000research.4856.2.
Full Text & Related Files:
Abstract: Thrombocytosis portends adverse prognostic significance in many types of cancers including ovarian and lung carcinoma. In this study, we determined the prevalence and prognostic significance of thrombocytosis (defined as platelet count in excess of 400 × 10 3/μl) in patients with colorectal cancer. We performed a retrospective analysis of 310 consecutive patients diagnosed at our Institution between 2004 and 2013. The patients (48.7% male and 51.3% female) had a mean age of 69.9 years (+/- 12.7 years) at diagnosis. Thrombocytosis was found in a total of 25 patients, with a higher incidence in those with stage III and IV disease (14.4% of patients). Although the mean platelet count increased with the depth of tumor invasion (pT), its values remained within normal limits in the whole patient cohort. No patient with stage I cancer (n=57) had elevated platelet count at diagnosis. By contrast, five of the 78 patients (6.4%) with stage II cancer showed thrombocytosis, and four of these patients showed early recurrence and/or metastatic disease, resulting in shortened survival (they died within one year after surgery). The incidence of thrombocytosis increased to 12.2% and 20.6%, respectively, in patients with stage III and IV disease. The overall survival rate of patients with thrombocytosis was lower than those without thrombocytosis in the stage II and III disease groups, but this difference disappeared in patients with stage IV cancer who did poorly regardless of their platelet count. We concluded that thrombocytosis at diagnosis indicates adverse clinical outcome in colorectal cancer patients with stage II or III disease. This observation is especially intriguing in stage II patients because the clinical management of these patients is controversial. If our data are confirmed in larger studies, stage II colon cancer patients with thrombocytosis may be considered for adjuvant chemotherapy.
Published Version: doi:10.12688/f1000research.4856.2
Other Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4240242/pdf/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:13581264
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters